Bone marrow involvement in patients with metastatic castration sensitive prostate cancer.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
29
12
2021
accepted:
22
06
2022
entrez:
21
7
2022
pubmed:
22
7
2022
medline:
26
7
2022
Statut:
epublish
Résumé
The clinical significance of bone marrow (BM) metastasis in prostate cancer as well as impact on oncological prognosis is unclear. We aim to assess the prevalence and clinical outcomes of BM metastasis at initial presentation of metastatic castrate sensitive prostate cancer (CSPC). Retrospective chart review of newly diagnosed metastatic CSPC patients was performed with collection of clinicopathologic and radiologic characteristics. Descriptive univariate and multivariate analysis was performed as well as survival measures (OS and PFS), which was done using the Kaplan-Meier survival and the Log-rank test. 189 patients were eligible, of which, eleven patients (6%) had biopsy proven BM involvement at diagnosis. There was a trend to poorer PFS and OS in patients with BM involvement but not statistically significant; however, factors that correlated with inferior PFS and OS in the multivariate analysis included ECOG PS, ALP, and Hb. BM metastasis in prostate cancer may lead to poorer survival. Clinical features including poor performance status, anemia, and elevated ALP, could guide bone marrow biopsies in the future to diagnose bone marrow metastasis at an earlier stage.
Identifiants
pubmed: 35862364
doi: 10.1371/journal.pone.0270956
pii: PONE-D-21-40910
pmc: PMC9302741
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0270956Déclaration de conflit d'intérêts
All the authors declare no conflict of interest.
Références
Int Urol Nephrol. 2019 Oct;51(10):1743-1753
pubmed: 31289983
Hematol Oncol. 1993 Jan-Feb;11(1):35-42
pubmed: 8325625
Iran J Pathol. 2018 Winter;13(1):78-84
pubmed: 29731799
Eur Urol. 2015 Aug;68(2):325-34
pubmed: 25108577
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Indian J Pathol Microbiol. 2014 Jul-Sep;57(3):396-9
pubmed: 25118730
Medicine (Baltimore). 2019 Sep;98(39):e17197
pubmed: 31574827
Cancer Med. 2017 May;6(5):918-927
pubmed: 28401701
Can Urol Assoc J. 2014 Mar-Apr;8(3-4):E137-41
pubmed: 24678352
Eur Urol. 2014 Feb;65(2):270-273
pubmed: 24295792
JAMA Oncol. 2017 Apr 01;3(4):524-548
pubmed: 27918777
J Clin Oncol. 2016 Apr 20;34(12):1402-18
pubmed: 26903579
Pathologe. 2017 Jul;38(4):317-323
pubmed: 28577052
Indian J Surg Oncol. 2021 Sep;12(3):545-548
pubmed: 34658583
J Cancer Res Ther. 2018 Jun;14(Supplement):S512-S515
pubmed: 29970716
BMC Cancer. 2005 Nov 01;5:144
pubmed: 16262899
Can Urol Assoc J. 2015 May-Jun;9(5-6):171-8
pubmed: 26225165
Cells. 2020 Sep 17;9(9):
pubmed: 32957584